Government initiatives asserting growth of Antivenom Market

Antivenom which is known as antivenin or venom antiserum, is a medicine that is made from antibodies and is used to treat venomous bites and stings. These are recommended only if there is presence of significant toxicity or there is a high risk of toxicity. The specific antivenom required also depends on the species involved in the stings and bites. It is predominantly given by injection. Antivenom Immunoglobin is described as the biological product that detoxifies poisoning of venomous bites. It is prepared by the milking venom of animals such as snakes, spiders, scorpions, and other venomous animals. Venomous bites can result in clinical conditions such as secretion of excessive saliva, muscle weakness, breathing problems, and other difficulties that might lead to death. Worldwide approximately 100,000 people die due to snake bites annually. To overcome the poisonous effects after venomous bites the manufacturers around the world have come up with a number of Antivenom products that include vaccines and hyperimmune sera. Let’s look into the global scenario of the antivenom market.

Increasing government initiatives to endorse the development of high quality antivenom products, occurrence of increasing number of snake bite victims especially in Asia-pacific and Africa, are driving the growth of the Antivenom Market globally. Antivenom products are not without their downsides and the withdrawal effect of antivenom products as a side effect are stunting the adoption rate of such concotions. There is also insufficient funding in this sector which combined with the high cost of the products, the increasingly regulatory complexities, and the non-apparent high costs of maintaining animal farms for the production of antivenom are restraining the growth this Market.

Side effects involving the Anti-venom may be severe. They include serum sickness, shortness of breath, and allergic reactions including anaphylaxis. Antivenom is produced by collecting venom from the appropriate animal and by then injecting small amounts of it into a domestic animal. The antibodies that form in the host animal are then collected from the blood and purified to make Anti-Venom products.

The market for Antivenom is broadly categorized into type of the product and the animal involved in its production. Vaccines and Hyperimmune Sera which is further segregated into Homologous & Heterologous are the two major product types in the Anti-Venom Market. Snakes, Scorpions, Spiders, and Others are categories when it comes to animals that are often but not always involved in such incidences that require antivenom.

Some of the key players that are actively involved in the ongoing development and innovation in this market are, Instituto Bioclon, S.A. de C.V. (Mexico), Pfizer AG (Switzerland), CSL Limited (Australia), F. Hoffmann-La Roche Ltd. (Switzerland), Merck & Co., Inc. (U.S.), Rare Disease Therapeutics, Inc. (U.S.), Vins Bioproducts Limited (India), BTG Plc (U.K.), Incepta Vaccine Ltd. (Bangladesh), and Bharat Serum and Vaccines Limited (BSV) (India). These companies are investing into research and development of the market and are consistently coming up with new products and efficient processes involved all around.

The market is expected to see a good growth in the coming years owing to the involvement of government and companies alike.

Check out Market Data Forecast’s comprehensive reports with in-depth analysis about the Antivenom Market a free research sample can also be availed. Stay tuned for trending news stories about the latest technologies and interesting Healthcare tit-bits.

Share this post:

Recent Posts

Leave a Comment

− 6 = 2